Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.
Did you mean: guided by a?

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

Orum Therapeutics a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and...

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, in partnership with FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today...

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Gilead Sciences, Inc. announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes...

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

PRM Pharma, LLC announces the nationwide availability of HemiClor® (chlorthalidone) 12.5 mg tablets, the first and only FDA-approved 12.5 mg formulation of chlorthalidone for the treatment of hypertension in adults. This milestone comes as the...

Real-world data presented at TCT 2025 demonstrates that the EggNest™ Complete Radiation Protection System significantly reduces radiation exposure for the entire cath lab

At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr. Jarrod Frizzell of The Christ Hospital (Cincinnati, OH) presented real-world studies¹,² demonstrating that the EggNest™ Complete Radiation Protection System from Egg...

2025 Interim Results and Business Updates Announced by Innovent

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases,...

The MosaiQ AiPlex® Vasculitis assay is now available for clinical use in the European Union and other countries accepting the CE mark

AliveDx, the global in vitro diagnostics company that aims to transform patient care, announces that the MosaiQ AiPlex® Vasculitis (VAS) assay achieved IVDR-CE Mark. This means that the MosaiQ AiPlex VAS assay is now available for clinical use in...

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Jiangsu Hengrui Pharmaceuticals Co., Ltd. a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based...

Innovent Announces Approval from China's NMPA for Mazdutide, the First Dual GCG/GLP-1 Receptor Agonist, for Chronic Weight Management

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major...

Genmab: Epcoritamab combo shows high response in R/R DLBCL patients eligible for ASCT

Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and...

AI Utilized by TNF Pharmaceuticals and Renova Health to Accelerate Drug Development

TNF Pharmaceuticals, Inc. a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify...

Novotech receives new investment from GIC, Temasek, and existing investor TPG to accelerate global growth

Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the...

PBZ OTC, the First New Topical Antihistamine in 50 Years, Unveiled by Kingsway Pharmaceuticals at Target Stores Nationwide

After 50 years, a new era in itch relief has arrived. PBZ OTC Pyribenzamine Antihistamine Cream, the first new topical antihistamine in half a century, is set to launch in April at Target stores across the United States. Powered by the trusted...

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

Axonal.AI today unveiled its groundbreaking platform, designed to significantly accelerate speed to market in the life sciences industry. At a time when rapid commercialization is more critical than ever, Axonal.AI's cutting-edge technology...

HNSA-5487 reduced IgG by over 95% in a first-in-human trial, showing redosing potential

Hansa Biopharma AB, announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing...

Galmed releases Phase 3 Aramchol results in Hepatology.

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients...

Solu Therapeutics appoints Sergio Santillana, MD, as Chief Medical Officer to strengthen its leadership team.

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment of Sergio Santillana, MD, MSc, MBA, as Chief Medical...

Corundum Systems Biology appoints Jessica Schneider as Chief Scientific Officer

Corundum Systems Biology, a leading investment company dedicated to advancing life-changing systems biology solutions for human health and well-being, today announced it has appointed Jessica Schneider, PhD, MPH as Chief Scientific Officer (CSO)....

MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that the company’s Life Science business achieved EXCiPACT cGMP (current Good Manufacturing Practice) certification for Pharmaceutical Auxiliary...

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that its Unidose Liquid System (Unidose) is the delivery system approved with neffy® (epinephrine nasal spray), the first and...

Results 21 - 40 of 46